New 2020 Product & Services Catalogs

Digital PDF

Digital Flipbook

Digital PDF

Download The 2020 Product Catalog
(Digital PDF)

DOWNLOAD (PDF)

Download The 2020 Services Catalog
(Digital PDF)

DOWNLOAD (PDF)

Digital Flipbook

View The 2020 Product Catalog
(Digital Flipbook)

VIEW DIGITAL FLIPBOOK

View The 2020 Services Catalog
(Digital Flipbook)

VIEW DIGITAL FLIPBOOK

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

Digital PDF

Digital Flipbook

Download The 2020
Product Catalog
(Digital PDF)

Download The 2020
Services Catalog
(Digital PDF)

View The 2020
Product Catalog
(Digital Flipbook)

View The 2020
Services Catalog
(Digital Flipbook)

Digital PDF

Download The 2020 Product Catalog
(Digital PDF)

Download The 2020 Services Catalog
(Digital PDF)

Digital Flipbook

View The 2020 Product Catalog
(Digital Flipbook)

View The 2020 Services Catalog
(Digital Flipbook)

Title

Global Search

SEARCH BY KEYWORD

Global Search

SEARCH BY KEYWORD

Looking for Product Documents?
Try our New Document Search Feature ⟶

Looking for Product Documents?
Try our New Document Search Feature ⟶

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

Digital PDF

Digital Flipbook

Download The 2020 Product Catalog (Digital PDF)

Download The 2020 Services Catalog (Digital PDF)

View The 2020 Product Catalog (Digital Flipbook)

View The 2020 Services Catalog (Digital Flipbook)

Digital PDF

Download The 2020 Product Catalog (Digital PDF)

Download The 2020 Services Catalog (Digital PDF)

Digital Flipbook

View The 2020 Product Catalog (Digital Flipbook)

View The 2020 Services Catalog (Digital Flipbook)

Title

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Download The 2020
Product Catalog
(Digital PDF)

Download The 2020
Services Catalog
(Digital PDF)

View The 2020
Product Catalog
(Digital Flipbook)

View The 2020
Services Catalog
(Digital Flipbook)

Download The 2020 Product Catalog
(Digital PDF)

Download The 2020 Services Catalog
(Digital PDF)

View The 2020 Product Catalog
(Digital Flipbook)

View The 2020 Services Catalog
(Digital Flipbook)